Concha Almarza, general manager at IQVIA Spain, discusses the changes that the Spanish pharmaceutical market has witnessed over the last few years, highlighting the stringent cost-containment measures aimed at improving patient access to complex innovative drugs, the stabilization of generics penetration urging producers to expand their offering to other segments, as well as the complexity of the fragmented healthcare system obliging every company to implement different market access strategies in each of the 17 autonomous regions.
You have been working at IQVIA since 2001 and became managing director in 2016. What are some of the current specificities of the Spanish pharmaceutical market that you had never imagined 16 years ago?
"Getting the right message to the right consumer, or the most appropriate treatment to each patient profile, is the base to improve results. Companies need technology to support new processes implementation."
